Efficacy of paracetamol for the treatment of patent ductus arteriosus in preterm neonates

Gianluca Terrin, Francesca Conte, Antonella Scipione, Erica Bacchio, Maria Giulia Conti, Rosalia Ferro, Flavia Ventriglia, Mario De Curtis, Gianluca Terrin, Francesca Conte, Antonella Scipione, Erica Bacchio, Maria Giulia Conti, Rosalia Ferro, Flavia Ventriglia, Mario De Curtis

Abstract

Inhibitors of the cyclo-oxygenase component of prostaglandin-H2 synthetase, namely indomethacin and ibuprofen, are commonly used in the treatment of hemodynamically significant patent ductus arteriosus. These drugs are associated with serious adverse events, including gastrointestinal perforation, renal failure and bleeding. The role of paracetamol, an inhibitor of the peroxidase component of prostaglandin-H2 synthetase, has been proposed for the treatment of patent ductus arteriosus. We report a series of 8 neonates (birth weight: 724 ± 173 g; gestational age: 26 ± 2 weeks) treated with paracetamol for a hemodynamically significant patent ductus arteriosus, because of contraindications to ibuprofen or indomethacin. Successful closure was achieved in 6 out of 8 babies (75%). Median ductal diameter was significantly reduced after treatment (from 1.2 mm, range 1.0-2.5 mm to 0.6 mm, range 0.0-2.5 mm, p = 0.038). No adverse or side effects were observed during treatment. On the basis of these results, paracetamol could be considered a promising and safe therapy for the treatment of patent ductus arteriosus in neonates.

References

    1. Hamrick SE, Hansmann G. Patent ductus arteriosus of the preterm infant. Pediatrics. 2010;125(5):1020–1030. doi: 10.1542/peds.2009-3506.
    1. Clyman RI. Mechanisms regulating the ductus arteriosus. Biol Neonate. 2006;89(4):330–335. doi: 10.1159/000092870.
    1. Graham GG, Davies MJ, Day RO, Mohamudally A, Scott KF. The modern pharmacology of paracetamol: therapeutic actions, mechanism of action, metabolism, toxicity and recent pharmacological findings. Inflammopharmacol. 2013;21(3):201–232. doi: 10.1007/s10787-013-0172-x.
    1. Van Overmeire B, Smets K, Lecoutere D, Van De Broek H, Weiler J, De Groote K, Langhendries JP. A comparison of ibuprofen and indhomethacin for closure of patent ductus arteriosus. N Engl J Med. 2000;343(10):674–681. doi: 10.1056/NEJM200009073431001.
    1. Ohlsson A, Walia R, Shah SS. Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane database Syst Rev. 2013;30(4):CD003481.
    1. Fujii AM, Brown E, Mirochnick M, O’Brien S, Kaufman G. Neonatal necrotizing enterocolitis with intestinal perforation in extremely premature infants receiving early indomethacin treatment for patent ductus arteriosus. J Perinatol. 2002;22(7):535–540. doi: 10.1038/sj.jp.7210795.
    1. Shorter NA, Liu JY, Mooney DP, Harmon BJ. Indomethacin-associated bowel perforations: a study of possible risk factors. J Pediatr Surg. 1999;34(3):442–444. doi: 10.1016/S0022-3468(99)90495-5.
    1. Bagnoli F, Rossetti A, Messina G, Mori A, Casucci M, Tomasini B. Treatment of patent ductus arteriosus (PDA) using ibuprofen: renal side-effects in VLBW and ELBW newborns. J Matern Fetal Neonatal Med. 2013;26(4):423–429. doi: 10.3109/14767058.2012.733775.
    1. Erdeve O, Sarici SU, Sari E, Gok F. Oral-ibuprofen-induced acute renal failure in a preterm infant. Pediatr Nephrol. 2008;23(9):1565–1567. doi: 10.1007/s00467-008-0835-9.
    1. Akima S, Kent A, Reynolds GJ, Gallagher M, Falk MC. Indomethacin and renal impairment in neonates. Pediatr Nephrol. 2004;19(5):490–493. doi: 10.1007/s00467-003-1402-z.
    1. Kanmaz G, Erdeve O, Canpolat FE, Oğuz SS, Uras N, Altug N, Greijdanus B, Dilmen U. Serum ibuprofen levels of extremely preterm infants treated prophylactically with oral ibuprofen to prevent patent ductus arteriosus. Eur J Clin Pharmacol. 2013;69(5):1075–1081. doi: 10.1007/s00228-012-1438-8.
    1. Hammerman C, Bin-Nun A, Markovitch E, Schimmel MS, Kaplan M, Fink D. Ductal closure with paracetamol: a surprising new approach to patent ductus arteriosus treatment. Pediatrics. 2011;128(6):e1618–e1621. doi: 10.1542/peds.2011-0359.
    1. Oncel MY, Yurttutan S, Degirmencioglu H, Uras N, Altug N, Erdeve O, Dilmen U. Intravenous paracetamol treatment in the management of patent ductus arteriosus in extremely low birth weight infants. Neonatology. 2013;103:165–168.
    1. Yurttutan S, Oncel MY, Arayıcı S, Uras N, Altug N, Erdeve O, Dilmen U. A different first-choice drug in the medical management of patent ductus arteriosus: oral paracetamol. J Matern Fetal Neonatal Med. 2013;26(8):825–827. doi: 10.3109/14767058.2012.755162.
    1. Oncel MY, Yurttutan S, Uras N, Altug N, Ozdemir R, Ekmen S, Erdeve O, Dilmen U. An alternative drug (paracetamol) in the management of patent ductus arteriosus in ibuprofen-resistant or contraindicated preterm infants. Arch Dis Child Fetal Neonatal Ed. 2013;98(1):F94. doi: 10.1136/archdischild-2012-302044.
    1. Sinha R, Negi V, Dalal SS. An interesting observation of PDA closure with oral paracetamol in preterm neonates. J Clin Neonatol. 2013;2(1):30–32. doi: 10.4103/2249-4847.109245.
    1. Tekgunduz KS, Ceviz N, Demirelli Y, Olgun H, Caner I, Sahin IO, Yolcu C. Intravenous paracetamol for patent ductus arteriosus in premature infants - a lower dose is also effective. Neonatology. 2013;104(1):6–7. doi: 10.1159/000348568.
    1. Ozdemir OM, Doğan M, Küçüktaşçı K, Ergin H, Sahin O. Paracetamol therapy for patent ductus arteriosus in premature infants: a chance before surgical ligation. Pediatr Cardiol. 2013. [Epub ahead of print]
    1. Alan S, Kahvecioglu D, Erdeve O, Atasay B, Arsan S. Is paracetamol a useful treatment for ibuprofen-resistant patent ductus arteriosus? Neonatology. 2013;104(3):168–169. doi: 10.1159/000352068.
    1. Roofthooft DW, van Beynum IM, Helbing WA, Reiss IK, Simons SH. Paracetamol for ductus arteriosus closure: not always a success story. Neonatology. 2013;104(3):170. doi: 10.1159/000353451.
    1. Dang D, Wang D, Zhang C, Zhou W, Zhou Q, Wu H. Comparison of oral paracetamol versus ibuprofen in premature infants with patent ductus arteriosus: a randomized controlled trial. PLoS One. 2013;8(11):e77888. doi: 10.1371/journal.pone.0077888.
    1. Oncel MY, Yurttutan S, Erdeve O, Uras N, Altug N, Oguz SS, Canpolat FE, Dilmen U. Oral paracetamol versus oral ibuprofen in the management of patent ductus arteriosus in preterm infants. A randomized controlled trial. J Pediatr. 2013. p. 01394-2. doi: 10.1016/j.jpeds.2013.11.008. [Epub ahead of print]
    1. McNamara PJ, Sehgal A. Towards rational management of the patent ductus arteriosus: the need for disease staging. Arch Dis Child Fetal Neonatal Ed. 2007;92(6):F424–F427. doi: 10.1136/adc.2007.118117.
    1. Koch J, Hensley G, Roy L, Brown S, Ramaciotti C, Rosenfeld CR. Prevalence of spontaneous closure of the ductus arteriosus in neonates at a birth weight of 1000 grams or less. Pediatrics. 2006;117(4):1113–1121. doi: 10.1542/peds.2005-1528.
    1. Dani C, Bertini G, Corsini I, Elia S, Vangi V, Pratesi S, Rubaltelli FF. The fate of ductus arteriosus in infants at 23-27 weeks of gestation: from spontaneous closure to ibuprofen resistance. Acta Paediatr. 2008;97(9):1176–1180. doi: 10.1111/j.1651-2227.2008.00871.x.
    1. Chorne N, Jegatheesan P, Lin E, Shi R, Clyman RI. Risk factors for persistent ductus arteriosus patency during indomethacin treatment. J Pediatr. 2007;151(6):629–634. doi: 10.1016/j.jpeds.2007.05.007.
    1. Van der Westhuizen J, Kuo PY, Reed PW, Holder K. Randomised controlled trial comparing oral and intravenous paracetamol (acetaminophen) plasma levels when given as preoperative analgesia. Anaesth Intensive Care. 2011;39(2):242–246.
    1. Echtler K, Stark K, Lorenz M, Kerstan S, Walch A, Jennen L, Rudelius M, Seidl S, Kremmer E, Emambokus NR, von Bruehl ML, Frampton J, Isermann B, Genzel-Boroviczény O, Schreiber C, Mehilli J, Kastrati A, Schwaiger M, Shivdasani RA, Massberg S. Platelets contribute to postnatal occlusion of the ductus arteriosus. Nat Med. 2010;16(1):75–82. doi: 10.1038/nm.2060.
    1. Clyman R, Chemtob S. Vessel remodeling in the newborn: platelets fill the gap. Nat Med. 2010;16(1):33–35. doi: 10.1038/nm0110-33.
    1. Strauss RG. Anaemia of prematurity: pathophysiology and treatment. Blood Rev. 2010;24(6):221–225. doi: 10.1016/j.blre.2010.08.001.
    1. Vandenberg KA. Individualized developmental care for high risk newborns in the NICU: a practice guideline. Early Hum Dev. 2007;83(7):433–442. doi: 10.1016/j.earlhumdev.2007.03.008.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever